Welcome in the 59th édition of our newsletter!
The AFM-Telethon and the ‘Sociétés de Projets Industriels’ SPI (Industrial Projects Companies) investment fund are creating YposKesi, the first French company to develop and produce gene and cell therapy products for rare diseases. This new company aims to make the first treatments available to patients and market them at a fair and controlled price, consistent with the commitment made by AFM-Téléthon and its founders’ characteristic general interest strategy.
